IFPMA celebrates 50 years with new report on acievements

29 May 2018

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), last week celebrated its 50th anniversary with the publication of a comprehensive report titled 50 Years of Global Health Progress.

The report gathers some of the main scientific advances achieved over these past five decades as well as those based on the research activity of the biopharmaceutical industry, and raises the major challenges faced by this sector.

The industry’s track record of partnerships over recent decades demonstrates what can be achieved by uniting governments, civil society and business, the report claims.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK